Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
Abstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-06-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-021-00286-w |
| _version_ | 1797421465333661696 |
|---|---|
| author | Fabio Puglisi Lorenzo Gerratana Matteo Lambertini Marcello Ceppi Luca Boni Filippo Montemurro Stefania Russo Claudia Bighin Michelino De Laurentiis Mario Giuliano Giancarlo Bisagni Antonio Durando Anna Turletti Ornella Garrone Andrea Ardizzoni Teresa Gamucci Giuseppe Colantuoni Adriano Gravina Sabino De Placido Francesco Cognetti Lucia Del Mastro |
| author_facet | Fabio Puglisi Lorenzo Gerratana Matteo Lambertini Marcello Ceppi Luca Boni Filippo Montemurro Stefania Russo Claudia Bighin Michelino De Laurentiis Mario Giuliano Giancarlo Bisagni Antonio Durando Anna Turletti Ornella Garrone Andrea Ardizzoni Teresa Gamucci Giuseppe Colantuoni Adriano Gravina Sabino De Placido Francesco Cognetti Lucia Del Mastro |
| author_sort | Fabio Puglisi |
| collection | DOAJ |
| description | Abstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS. |
| first_indexed | 2024-03-09T07:17:50Z |
| format | Article |
| id | doaj.art-76849692dd90493e9b9efa13c03d952c |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-09T07:17:50Z |
| publishDate | 2021-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-76849692dd90493e9b9efa13c03d952c2023-12-03T08:21:59ZengNature Portfolionpj Breast Cancer2374-46772021-06-01711910.1038/s41523-021-00286-wComposite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi0Lorenzo Gerratana1Matteo Lambertini2Marcello Ceppi3Luca Boni4Filippo Montemurro5Stefania Russo6Claudia Bighin7Michelino De Laurentiis8Mario Giuliano9Giancarlo Bisagni10Antonio Durando11Anna Turletti12Ornella Garrone13Andrea Ardizzoni14Teresa Gamucci15Giuseppe Colantuoni16Adriano Gravina17Sabino De Placido18Francesco Cognetti19Lucia Del Mastro20Department of Medicine (DAME), University of UdineDepartment of Medicine (DAME), University of UdineDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of GenoaClinical Epidemiology Unit, IRCCS Ospedale Policlinico San MartinoClinical Epidemiology Unit, IRCCS Ospedale Policlinico San MartinoDay Hospital Oncologico Multidisciplinare, Istituto di Candiolo, FPO-IRCCSDepartment of Oncology, ASU FC University HospitalOncologia Medica 2, IRCCS Ospedale Policlinico San MartinoDepartment of Breast Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”Department of Clinical Medicine and Surgery, University of Naples Federico IIAUSL-IRCCS Reggio EmiliaBreast Unit Ospedale S Anna, Citta’ della Salute e della Scienza di TorinoBreast Unit, ASL Citta’ di TorinoBreast Unit, Department of Medical Oncology AO S. Croce e Carle Ospedale di InsegnamentoMedical Oncology, S.Orsola University HospitalDepartment of Medical Oncology, Sandro Pertini Hospital and S. Eugenio Hospital, ASL Roma2Medical Oncology, Azienda Ospedaliera S Giuseppe MoscatiClinical Trial Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”Department of Clinical Medicine and Surgery, University of Naples Federico IIDepartment of Medical Oncology, Istituto Regina Elena per lo Studio e la Cura dei TumoriDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of GenoaAbstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.https://doi.org/10.1038/s41523-021-00286-w |
| spellingShingle | Fabio Puglisi Lorenzo Gerratana Matteo Lambertini Marcello Ceppi Luca Boni Filippo Montemurro Stefania Russo Claudia Bighin Michelino De Laurentiis Mario Giuliano Giancarlo Bisagni Antonio Durando Anna Turletti Ornella Garrone Andrea Ardizzoni Teresa Gamucci Giuseppe Colantuoni Adriano Gravina Sabino De Placido Francesco Cognetti Lucia Del Mastro Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer npj Breast Cancer |
| title | Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer |
| title_full | Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer |
| title_fullStr | Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer |
| title_full_unstemmed | Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer |
| title_short | Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer |
| title_sort | composite risk and benefit from adjuvant dose dense chemotherapy in hormone receptor positive breast cancer |
| url | https://doi.org/10.1038/s41523-021-00286-w |
| work_keys_str_mv | AT fabiopuglisi compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT lorenzogerratana compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT matteolambertini compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT marcelloceppi compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT lucaboni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT filippomontemurro compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT stefaniarusso compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT claudiabighin compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT michelinodelaurentiis compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT mariogiuliano compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT giancarlobisagni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT antoniodurando compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT annaturletti compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT ornellagarrone compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT andreaardizzoni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT teresagamucci compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT giuseppecolantuoni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT adrianogravina compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT sabinodeplacido compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT francescocognetti compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT luciadelmastro compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer |